The latest shared research on Vaccines
Scrip Roundtable Cancer Vaccines: Future Role – How Will Treatment Strategies Change with the Arrival of Cancer Vaccines?
Five industry experts, representing market analysts, venture capital, biotech, private healthcare and pharma, debated the role of cancer vaccines in the war on cancer, what is holding back their development, what has been achieved thus far, and scientific, clinical and commercial challenges they still face. The debate was chaired by Scrip’s editor-in-chief Mike Ward. Our panel comprised the following experts: Andrew Paramore, Datamonitor Dr Christina Takke, Forbion Capital Partners Dr Dana Leach, KAEL-GemVax Professor Karol Sikora, CancerPartnersUK Matthew McCourt, MedImmune Mike Ward, Scrip Intelligence Future role: how will treatment strategies change with the arrival of cancer vaccines? Cancer vaccines will take their place in the treatment armoury but personalisation ...
Scrip Roundtable Cancer Vaccines: Pharma’s Role – What Part Should Industry Play in Cancer Vaccine Development?
Five industry experts, representing market analysts, venture capital, biotech, private healthcare and pharma, debated the role of cancer vaccines in the war on cancer, what is holding back their development, what has been achieved thus far, and scientific, clinical and commercial challenges they still face. The debate was chaired by Scrip’s editor-in-chief Mike Ward. Our panel comprised the following experts: Andrew Paramore, Datamonitor Dr Christina Takke, Forbion Capital Partners Dr Dana Leach, KAEL-GemVax Professor Karol Sikora, CancerPartnersUK Matthew McCourt, MedImmune Mike Ward, Scrip Intelligence Pharma's role: what part should industry play in cancer vaccine development? Pharma's drug discovery model has left it on the ...
Scrip Roundtable Cancer Vaccines: Show Me the Money – Will Cancer Vaccines be Rainmakers?
Five industry experts, representing market analysts, venture capital, biotech, private healthcare and pharma, debated the role of cancer vaccines in the war on cancer, what is holding back their development, what has been achieved thus far, and scientific, clinical and commercial challenges they still face. The debate was chaired by Scrip’s editor-in-chief Mike Ward. Our panel comprised the following experts: Andrew Paramore, Datamonitor Dr Christina Takke, Forbion Capital Partners Dr Dana Leach, KAEL-GemVax Professor Karol Sikora, CancerPartnersUK Matthew McCourt, MedImmune Mike Ward, Scrip Intelligence Show me the money: will cancer vaccines be rainmakers? Good efficacy and good biomarkers will be crucial for proving cost-effectiveness ...
Scrip Roundtable Cancer Vaccines: Challenges – What’s Holding Back Development?
Five industry experts, representing market analysts, venture capital, biotech, private healthcare and pharma, debated the role of cancer vaccines in the war on cancer, what is holding back their development, what has been achieved thus far, and scientific, clinical and commercial challenges they still face. The debate was chaired by Scrip’s editor-in-chief Mike Ward. Our panel comprised the following experts: Andrew Paramore, Datamonitor Dr Christina Takke, Forbion Capital Partners Dr Dana Leach, KAEL-GemVax Professor Karol Sikora, CancerPartnersUK Matthew McCourt, MedImmune Mike Ward, Scrip ...
Scrip Roundtable Cancer Vaccines: A New Weapon in the War on Cancer?
Five industry experts, representing market analysts, venture capital, biotech, private healthcare and pharma, debated the role of cancer vaccines in the war on cancer, what is holding back their development, what has been achieved thus far, and scientific, clinical and commercial challenges they still face. The debate was chaired by Scrip's editor-in-chief Mike Ward. Our panel comprised the following experts: Andrew Paramore, Datamonitor Dr Christina Takke, Forbion Capital Partners Dr Dana Leach, KAEL-GemVax Professor Karol Sikora, CancerPartnersUK Matthew McCourt, MedImmune Mike Ward, Scrip Intelligence Meet the roundtable panelists ...
Sanofi Builds Sales and Distribution Platform to Surf China’s Market Growth
Wang Fangqing Sanofi is planning to accelerate its expansion into both the prescription and general healthcare sectors in China, as part of which it is aiming for revenues of about €100 million ($141 million) from its consumer healthcare business in the country. Vaccines are another important area of focus for the French group, and its Sanofi-Pasteur arm has recently launched Pentaxim, the first paediatric five-in-one (diphtheria, tetanus, pertussis, polio and Haemophilus influenzae type b) vaccine to be commercialised in China. Apart from vaccines, Sanofi has been developing its prescription drug business in areas including diabetes, hypertension and cancer, which are now among ...
Novartis: strengthening vaccines presence in the lucrative Chinese market
Swiss-based Novartis has acquired a majority stake in a Chinese vaccines company. Novartis has completed the acquisition of an 85% stake in the Chinese vaccines company Zhejiang Tianyuan Bio-Pharmaceuticals. Faced with limited growth opportunities in the Western markets, all major vaccines players are expanding activities into growth markets due to the high incidence of vaccine-preventable diseases and increasing public and private healthcare spending. Zhejiang Tianyuan Bio-Pharmaceuticals is a privately owned vaccines company offering a range of marketed vaccine products in China and a pipeline focused on various preventable viral and bacterial diseases. Pharmaceutical companies have traditionally focused on the Western markets as patients ...
